UPSTREAM BIO, INC. Research and Development Expense
UPSTREAM BIO, INC. (UPB) reported Research and Development Expense of $36.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- UPSTREAM BIO, INC. research and development expense for the quarter ending 2026-06-30 was $36.09M, a 4.69% decline year-over-year.
- UPSTREAM BIO, INC. research and development expense for the quarter ending 2026-03-31 was $36.56M, a 41.74% increase year-over-year.
- UPSTREAM BIO, INC. research and development expense for the quarter ending 2025-12-31 was $40.17M, a 84.49% increase year-over-year.
- UPSTREAM BIO, INC. research and development expense for the quarter ending 2025-09-30 was $32.98M, a 113.67% increase year-over-year.
- UPSTREAM BIO, INC. research and development expense for fiscal 2025 was $136.81M, a 117.27% increase from fiscal 2024.
- UPSTREAM BIO, INC. research and development expense for fiscal 2024 was $62.97M, a 98.01% increase from fiscal 2023.
- UPSTREAM BIO, INC. research and development expense for fiscal 2023 was $31.80M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.09M 10-Q · filed 2026-08-11 | $72.65M 10-Q · filed 2026-08-11 | $112.82M derived: sum of 3 quarters · filed 2026-08-11 | $145.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $36.56M 10-Q · filed 2026-05-13 | $76.73M derived: sum of 2 quarters · filed 2026-05-13 | $109.71M derived: sum of 3 quarters · filed 2026-05-13 | $147.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $40.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $73.14M derived: sum of 2 quarters · filed 2026-03-26 | $111.01M derived: sum of 3 quarters · filed 2026-08-11 | $136.81M 10-K · filed 2026-03-26 |
| 2025-09-30 | $32.98M 10-Q · filed 2025-11-05 | $70.84M derived: sum of 2 quarters · filed 2026-08-11 | $96.64M 10-Q · filed 2025-11-05 | $118.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $37.87M 10-Q · filed 2026-08-11 | $63.66M 10-Q · filed 2026-08-11 | $85.44M derived: sum of 3 quarters · filed 2026-08-11 | $100.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $25.80M 10-Q · filed 2026-05-13 | $47.57M derived: sum of 2 quarters · filed 2026-05-13 | $63.00M derived: sum of 3 quarters · filed 2026-05-13 | $77.07M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $21.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $37.21M derived: sum of 2 quarters · filed 2026-03-26 | $51.27M derived: sum of 3 quarters · filed 2026-03-26 | $62.97M 10-K · filed 2026-03-26 |
| 2024-09-30 | $15.43M 10-Q · filed 2025-11-05 | $29.50M derived: sum of 2 quarters · filed 2025-11-05 | $41.19M 10-Q · filed 2025-11-05 | $52.75M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $14.07M 10-Q · filed 2025-08-06 | $25.76M 10-Q · filed 2025-08-06 | $37.31M derived: sum of 3 quarters · filed 2025-08-06 | $45.10M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $11.69M 10-Q · filed 2025-05-06 | $23.25M derived: sum of 2 quarters · filed 2025-05-06 | $31.03M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $19.34M derived: sum of 2 quarters · filed 2025-03-12 | $31.80M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $7.79M 10-Q · filed 2024-11-07 | $20.25M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |